Oral eplerenone for the management of chronic central serous chorioretinopathy

AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR). METHODS: A retrospective consecutive case series was conducted for patients receiving oral eplerenone for chronic CSCR. At baseline and eac...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Ophthalmol
Asıl Yazarlar: Singh, Rishi P, Sears, Jonathan E, Bedi, Rumneek, Schachat, Andrew P, Ehlers, Justis P, Kaiser, Peter K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: International Journal of Ophthalmology Press 2015
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4413566/
https://ncbi.nlm.nih.gov/pubmed/25938046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3980/j.issn.2222-3959.2015.02.17
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller